John Crabb, Ph.D.

John Crabb, PhD, joined Cleveland Clinic in 1998 as a full Staff member in the Department of Ophthalmic Research, Cole Eye Institute, with a secondary appointment in the Department of Cell Biology, Lerner Research Institute. He is a full Faculty member and Professor in the Department of Chemistry, Case Western Reserve University, and in the Departments of Ophthalmology and Molecular Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds adjunct professorships in the Department of Chemistry, Cleveland State University, and the School of Biomedical Sciences, Kent State University.   

A major focus of Dr. Crabb's research concerns age-related macular degeneration (AMD). Proteomic biomarker studies are directed toward developing a blood test for AMD to identify those at risk, before there is clinical evidence of the disease. Other proteomic studies in his laboratory focus on glaucoma biomarker discovery and the molecular details of the retinoid visual cycle. Information about the laboratory can be found online at www.lerner.ccf.erg/eye/crabb/.

Dr. Crabb received a Bachelor's Degree in biology and chemistry from Lewis & Clark College in Portland, Ore., and a doctorate in microbiology from the University of Kansas Medical Center, Kansas City, Kan. He pursued postdoctoral training in biological chemistry at the University of Michigan and in the biochemistry of vision at the University of Washington. Prior to joining the Cole Eye Institute, he was a Senior Scientist and Director of Protein Chemistry at the Adirondack Biomedical Research Institute in Lake Placid, N.Y. During the 14 years he was in upstate New York, Dr. Crabb maintained adjunct faculty appointments at the University of Vermont, Clarkson University and Albany Medical College. Prior to New York, he was an Assistant Professor and Director of the Protein Sequencing Facility in the Institute of Physiological Chemistry, Ruhr University, Bochum, Germany.

Dr. Crabb has served full 5-year terms on NSF and NIH grant review panels and is a member of the editorial boards of Experimental Eye Research and the Journal of Ocular Biology, Disease and Informatics. He has published more than 190 basic-science research articles and currently has research support from government, private and corporate sources.

• Editorial Board, Experimental Eye Research, 1998-Present
• Editorial Board, Journal of Ocular Biology, Diseases and Informatics, 2007-Present

• Postdoctoral Scholar, Department of Biological Chemistry, University of Michigan, Ann Arbor, Mich., protein chemistry (mentor, M.J. Coon), 1978-1980
  
• Senior Fellow, Department of Ophthalmology, University of Washington, Seattle, Wash., biochemistry of vision (mentor, J.C. Saari), 1980-1982

Age-related macular degeneration primary open angle glaucoma.

• U.S. Patent No. 7172874, Diagnostic Methods for Age Related Macular Degeneration, by Hollyfield JG, Salomon RG, Crabb JW, Gu X; granted February 6, 2007
• Crabb JW, Salomon RG, Anand-Apte B, Ebrahem Q, Reganathan K (2006), Composition and Methods for Macular Degeneration. US Provisional Patent Application 60/832,898, filed 07/26/06
• Kuttner-Kondo L, Hagstrom S, Crabb JW, Hollyfield JG, Medof ME (2007), Methods for Detecting Age Related Macular Degeneration in a Subject. US Provisional Patent Application, filed 03/02/07
• Bhattacharya SK, Crabb JW (2006), Compositions and  Methods for Inhibiting Optic Nerve Damage. US Provisonal Patent Application 60/773,359, filed 02/13/06; International Application PCT/US2007/003834, filed 2/12/07; International Publication Number WO 2007/095250, published 8/23/07

• Sandy and Tom Trudell Research Award, Foundation Fighting Blindness, 2003   
• Steinbach Award, Ruth and Milton Steinbach, 2006-2009
• Senior Investigator Award, Research to Prevent Blindness, 2007

• American Society for Biochemistry and Molecular Biology
• American Society for Mass Spectrometry
• Association of Biomolecular Resource Facilities
• Association for Research in Vision and Ophthalmology
• The Protein Society

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 7/31/2008, Dr. Crabb has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting.  Dr. Crabb receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:

• Alcon Laboratories

Royalty Payments.  Dr. Crabb has the right to receive royalty payments for inventions or discoveries related to the companies shown below:

• Frantz Biomarkers, LLC
• Genentech, Inc.

Equity.  Dr. Crabb owns stock or stock options in the following companies for activities as a founder, inventor, or consultant:

• Sirion Therapeutics

( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)